Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the efficacy of the drug Droxidopa (Northera) in
increasing blood pressure in subject with hypotension, low blood pressure, which is
classified as blood pressure less than 110/70 in males and 100/70 in females. The first aim
is to determine the proportion of subject with Spinal Cord Injury (SCI) who have a
normotensive response to Droxidopa. The second is to determine the proportion of subject with
SCI who express a hypertensive response to Droxidopa. A Normal blood pressure ranges from
111-139 in males and 101-139 in females and a hypertensive blood pressure is anything higher
than 140 in males and females.
The study would take place in James J. Peters VA Medical Center (JJPVAMC) and The Icahn
School of Medicine at Mount Sinai (ISMMS) in Manhattan, New York.